Description

Clinical Evidence

• In a double-blind, placebo-controlled trial, Selank demonstrated significant reduction in anxiety symptoms in patients with generalized anxiety disorder (GAD).
• Studies show Selank enhances BDNF (brain-derived neurotrophic factor) expression, which may contribute to its cognitive and antidepressant-like properties.
• Animal models indicate Selank improves memory consolidation and retrieval, particularly under stress conditions.
• Selank also exhibits antiviral activity, particularly against influenza and herpes viruses, in part by modulating interferon gamma (IFN-γ) and other immune mediators.
• Selank’s unique profile as an immune-active neuropeptide has sparked interest in its dual nootropic and adaptogenic potential in peptide research.

Potential Side Effects

In both animal and early human studies, Selank has shown an exceptional safety profile, with minimal to no adverse effects observed. Potential effects in research contexts include:

• Mild nasal irritation (when administered intranasally)
• Rare headache or dizziness at high doses
• Transient changes in mood or alertness in sensitive models
• No tolerance, dependence, or withdrawal symptoms have been reported in clinical literature.

Disclaimer

Selank is intended for laboratory research use only. It is not approved for human consumption or therapeutic use. All referenced effects are based on preclinical and exploratory human studies. This product must be handled by qualified professionals in a controlled research setting.